12:00 AM
Aug 03, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Brentuximab vedotin: Phase II started

Seattle Genetics began an open-label, U.S. Phase II trial (SGN35-006) to evaluate 1.8 mg/kg IV brentuximab vedotin given every 3 weeks in up to 50 relapsed patients who previously achieved a complete...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >